Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
1. A pharmaceutical composition comprising stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a propellant, wherein the pharmaceutical composition is an aerosol dosage form.
2. The pharmaceutical composition of claim 1 , wherein the propellant comprises a halogenated hydrocarbon.
3. The pharmaceutical composition of claim 2 , wherein the propellant is selected from the group consisting of trichloromonofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane, and combinations thereof.
4. The pharmaceutical composition of claim 1 , wherein the propellant is trichloromonofluoromethane, dichlorodifluoromethane, and dichlorotetrafluoromethane.
5. The pharmaceutical composition of claim 1 comprising:
a. 0.17 wt. % (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione,
b. 24.20 wt. % trichloromonofluoromethane,
c. 53.11 wt. % dichlorodifluoromethane, and
d. 22.52 wt. % dichlorotetrafluoroethane.